Cyclohexane lipidoids for nucleic acid transfection and use thereof
A lipidoid of general formula I, where X is selected from —C(═O)NH—,—C(═O)O—, —C(═S)O—, —C(═O)S—, —C(═S)S—, —C(═O)NHNH—, —CH 2 —, —O—, —OC(═O)—, —S—, —SC(═O)—, —NH—, —NHNH—, —NHC(═O)—, —NHNHC(═O)—, —C≡C—, —CH═CH—, a five-membered heterocycle containing at least 2 nitrogen atoms, —CH 2 C(═O)NH—, —CH 2 C(═S)O—, —CH 2 C(═S)S—, —CH 2 C(═O)NHNH—, —N═CH—, —CH═N—, —NH—N═CH—, and —CH═N—NH—; Y is alkylene C 2 -C 10 chain; R 1 is selected from alkyl C 1 -C 46 , alkenyl C 2 -C 46 , alkynyl C 2 -C 46 ; Z is selected from H, —OH, —CH 3 , —CH 2 OH, —NH 2 , —C(═O)NH 2 , CONH(CH 2 ) 2 OH, —CON[(CH 2 ) 2 OH] 2 , —CONHCH(CH 2 OH) 2 , —CONHCH 2 CH(—OH)CH 2 OH, —CONH(CH 2 ) 2 C(═O)NH 2 , —CON[CH 2 C(═O)NH 2 ] 2 , —CONH(CH 2 ) 2 NHC(═O)NH 2 , —CONH(CH 2 ) 3 —N+(CH 3 ) 2 —(CH 2 ) 2 —SO 3 —, —CONH(CH 2 ) 3 —N+(CH 3 ) 2 —(CH 2 ) 2 —COO—, —COO(CH—COO(CH 2 ) 2 —O—P(═O)(O—)—O(CH 2 ) 2 —N+(CH 3 ) 3 , —N+(CH 3 ) 2 —(CH 2 ) 3 —SO 3 —, —N+(CH 3 ) 2 —(CH 2 ) 2 —COO—. Transfection reagents, transfection particles containing this lipidoid are also described.
1 . Lipidoids of general formula (I)
wherein
X is selected from the group comprising —C(═O)NH—, —C(═O)O—, —C(═S)O—, —C(═O)S—, —C(═S)S—, —C(═O)NHNH—, —CH 2 —, —O—, —OC(═O)—, —S—, —SC(═O)—, —NH—, —NHNH—, —NHC(═O)—, —NHNHC(═O)—, —C≡C—, —CH═CH—, a five-membered heterocycle containing at least 2 nitrogen atoms, —CH 2 C(═O)NH—, —CH 2 C(═O)O—, —CH 2 C(═S)O—, —CH 2 C(═S)S—, —CH 2 C(═O)NHNH—, —N═CH—, —CH═N—, —NH—N═CH—, and —CH═N—NH—;
Y is selected from the group consisting of C 2 -C 10 alkylene chains, wherein the alkylene chain, one or more —CH 2 — groups may optionally be replaced with one or more O and/or S atoms;
R 1 are the same or different from each other, each R 1 being independently selected from the group consisting of C 1 -C 46 alkyl, C 2 -C 46 alkenyl, C 2 -C 46 alkynyl, wherein the alkyl, alkenyl or alkynyl may be linear or branched, and wherein in the alkyl, alkenyl or alkynyl, one or more —CH 2 — groups may be replaced with CH(OH), —OC(═O)—, —C(═O)O—, —S—S—, —C(═O)NH—, —NHC(═O)—, —O—, and —S—;
wherein if R 1 is C 1 -C 4 alkyl, then one hydrogen from the terminal —CH 3 group may be substituted with Z;
with the proviso that at least one R 1 contains at least 8 carbon atoms;
Z are the same or different from each other, each Z being independently selected from the group comprising hydrogen, —OH, —CH 3 , —CH 2 OH, —NH 2 , —C(═O)NH 2 , —CONH(CH 2 ) 2 OH, —CON[(CH 2 ) 2 OH] 2 , —CONHCH(CH 2 OH) 2 , —CONHCH 2 CH(—OH)CH 2 OH, —CONH(CH 2 ) 2 C(═O)NH 2 , —CON[CH 2 C(═O)NH 2 ] 2 , —CONHCH[C(═O)NH 2 ] 2 , —CONH(CH 2 ) 2 NHC(═O)NH 2 , —CONH(CH 2 ) 3 —N + (CH 3 ) 2 —(CH 2 ) 2 —SO 3 − , —CONH(CH 2 ) 3 —N + (CH 3 ) 2 —(CH 2 ) 3 —SO 3 − , —CONH(CH 2 ) 3 —N + (CH 3 ) 2 —(CH 2 ) 2 —COO − , —COO(CH 2 ) 2 —O—P(═O)(O − )—O(CH 2 ) 2 —N + (CH 3 ) 3 , —N + (CH 3 ) 2 —(CH 2 ) 3 —SO 3 − , —N + (CH 3 ) 2 —(CH 2 ) 2 —COO − ,
wherein
R 2 is independently selected from hydrogen and —CH 3 ;
E is independently selected from O and S atoms;
n is an integer within the range of from 1 to 5;
and T are the same or different from each other, each T being independently selected from the group comprising —X—Y—N(R 1 ) 2 , —C(═O)O(C 1 -C 3 alkyl), —C(═O)OCH 2 CH 2 OH, —C(═O)NH 2 ,
—C(═O)OH, —CONH(CH 2 ) 2 OH, —CON[(CH 2 ) 2 OH] 2 , —CONHCH(CH 2 OH) 2 , —CONHCH 2 CH(—OH)CH 2 OH, —CONH(CH 2 ) 2 C(═O)NH 2 , —CON[CH 2 C(═O)NH 2 ] 2 , —CONHCH[C(═O)NH 2 ] 2 , —CONH(CH 2 ) 2 NHC(═O)NH 2 , —CONH(CH 2 ) 3 —N + (CH 3 ) 2 —(CH 2 ) 2 —SO 3 − , —CONH(CH 2 ) 3 —N + (CH 3 ) 2 —(CH 2 ) 3 —SO 3 − , —CONH(CH 2 ) 3 —N + (CH 3 ) 2 —(CH 2 ) 2 —COO − , —COO(CH 2 ) 2 —O—P(═O)(O—)—O(CH 2 ) 2 —N + (CH 3 ) 3 ,
—OH, —O(C 1 -C 3 alkyl), —NH 2 , —NHC(═O)CH 3 , —NHS(═O) 2 CH 3 , —NHC(═O)N(CH 3 ) 2 , —NHC(═O)NH(CH 3 ), —NHC(═S)N(CH 3 ) 2 , —NHC(═S)NH(CH 3 ), —NHC(═N—CN)NH 2 , —NHC(═N—CN)NH(CH 3 ), —NHC(═N—CN)N(CH 3 ) 2 , —NHC[═N—S(═O) 2 NH 2 ]NH 2 , —N + (CH 3 ) 2 —(CH 2 ) 3 —SO 3 − , —N + (CH 3 ) 2 —(CH 2 ) 2 —COO − , and
wherein R 2 , E and n are as defined above;
and/or if Z is —OH or —CH 2 OH, and T is —C(═O)OH, then Z together with T and three carbon atoms between them may form a cyclic lactone containing 4 to 5 carbon atoms;
and pharmaceutically acceptable salts, addition salts and solvates thereof.
2 . The lipidoid according to claim 1 , wherein X is selected from the group consisting of —C(═O)NH—, —C(═O)O—, —C(═O)NHNH—, —OC(═O)—, —O—, —NHC(═O)—, —NHNHC(═O)—, and a five-membered heterocycle containing at least 2 nitrogen atoms.
3 . The lipidoid according to claim 1 , wherein R 1 are independently selected from the group consisting of C 1 -C 46 alkyl, and C 2 -C 46 alkenyl, wherein in the said alkyl or alkenyl, one or more —CH 2 — groups may optionally be replaced with —C(═O)O—.
4 . The compound according to claim 1 , wherein all R 1 in the compound are the same.
5 . The compound according to claim 1 , wherein Z is selected from the group consisting of
hydrogen, —OH, —CH 3 , —CH 2 OH, —NH 2 , —C(═O)NH 2 , —CONH(CH 2 ) 2 OH, —CON[(CH 2 ) 2 OH] 2 , —CONHCH(CH 2 OH) 2 , —CONHCH 2 CH(—OH)CH 2 OH, —CONH(CH 2 ) 2 C(═O)NH 2 , —CON[CH 2 C(═O)NH 2 ] 2 , —CONHCH[C(═O)NH 2 ] 2 , —CONH(CH 2 ) 2 NHC(═O)NH 2 , —N + (CH 3 ) 2 —(CH 2 ) 3 —SO 3 − , —N + (CH 3 ) 2 —(CH 2 ) 2 —COO − ,
wherein R 2 , E and n are as defined in claim 1 .
6 . The lipidoid according to claim 1 , wherein T is selected from the group consisting of —X—Y—N(R 1 ) 2 , —C(═O)O(C 1 -C 3 alkyl), —C(═O)OCH 2 CH 2 OH, —C(═O)NH 2 ,
—C(═O)OH, —CONH(CH 2 ) 2 OH, —CON[(CH 2 ) 2 OH] 2 , —CONHCH(CH 2 OH) 2 , —CONHCH 2 CH(—OH)CH 2 OH, —CONH(CH 2 ) 2 C(═O)NH 2 , —CON[CH 2 C(═O)NH 2 ] 2 , —CONHCH[C(═O)NH 2 ] 2 , —CONH(CH 2 ) 2 NHC(═O)NH 2 , —CONH(CH 2 ) 3 —N + (CH 3 ) 2 —(CH 2 ) 2 —SO 3 − ,
—CONH(CH 2 ) 3 —N + (CH 3 ) 2 —(CH 2 ) 3 —SO 3 − , —CONH(CH 2 ) 3 —N + (CH 3 ) 2 —(CH 2 ) 2 —COO − , —COO(CH 2 ) 2 —O—P(═O)(O—)—O(CH 2 ) 2 —N + (CH 3 ) 3 , and
wherein R 2 , E and n are as defined in claim 1 .
7 . The compound according to claim 1 , wherein at least one T is —X—Y—N(R 1 ) 2 .
8 . The compound according to claim 1 , wherein Z is selected from the group consisting of hydrogen, —OH, —CH 3 , and —CH 2 OH;
and T is selected from the group consisting of —X—Y—N(R 1 ) 2 , —C(═O)O(C 1 -C 3 alkyl),
and —C(═O)OH;
and/or if Z is —OH or —CH 2 OH, and T is —C(═O)OH, then Z together with T and three carbon atoms between them may form a cyclic lactone containing 4 to 5 carbon atoms.
9 . The lipidoid according to claim 1 , wherein:
X is —C(═O)NH— or —NHC(═O)—;
Y is selected from —(CH 2 ) 3 —, —(CH 2 ) 4 —, —(CH 2 ) 5 —, and —(CH 2 ) 6 —;
R 1 is selected from the group comprising linear or branched C 10 -C 15 alkyl; and linear or branched C 12 -C 18 alkenyl;
wherein in the alkyl or alkenyl, one or more —CH 2 — groups may be replaced with —C(═O)O—;
T is selected from —X—Y—N(R 1 ) 2 , —C(═O)OCH 3 ,
and —C(═O)OH;
Z is selected from H, —CH 3 , and —CH 2 OH.
10 . The compound according to claim 1 , wherein the compund of general formula (I) contains at least two R 1 substituents, each of them containing at least 8 carbon atoms.
11 . A transfection agent comprising at least one compound of general formula (I) according to claim 1 , and at least one helper lipid; wherein the helper lipid is selected from the group comprising cholesterol, β-sitosterol, stigmastanol, campesterol, fucosterol, avenasterol, fecosterol, brassicasterol, ergosterol, 9,11-dehydroergosterol, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dimyristoyl-rac-glycero-3-methoxy poly (ethyleneglycol)-2000, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-poly (ethyleneglycol)-2000, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine poly (ethyleneglycol)-2000, and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine poly (ethyleneglycol)-2000.
12 . The transfection agent according to claim 11 , comprising at least one compound of general formula (I) in an amount of from 10 to 50 mol. %, and at least one helper lipid in an amount of from 50 to 90 mol. %.
13 . The transfection agent according to claim 11 , comprising at least one compound of general formula (I) in an amount of from 15 to 40 mol. %, cholesterol in an amount of from 30 to 55 mol. %, and at least one other helper lipid in an amount of from 20 to 50 mol. %; wherein the helper lipid is selected from the group comprising β-sitosterol, stigmastanol, campesterol, fucosterol, avenasterol, fecosterol, brassicasterol, ergosterol, 9,11-dehydroergosterol, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dimyristoyl-rac-glycero-3-methoxy poly (ethyleneglycol)-2000, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-poly (ethyleneglycol)-2000, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine poly (ethyleneglycol)-2000, and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine poly (ethyleneglycol)-2000.
14 . A transfection particle comprising at least one compound of general formula (I) according to claim 1 , at least one nucleic acid and/or a part thereof and/or nucleic acid derivative; and also at least one helper lipid.
15 . A method of administering a medicament comprising the compound of general formula (I) according to claim 1 for in vitro transfection of cells or tissues with nucleic acid and/or a part thereof and/or nucleic acid derivative.
16 . A method of administering a medicament comprising the compound of general formula (I) according to claim 1 for silencing or activating chromosomal gene(s), silencing or activating immunogenes, inhibiting or activating signaling pathways, editing genome or transcriptome, or enabling the expression of the protein(s) encoded by a nucleic acid.
17 . A method of administering a medicament comprising the compound of general formula (I) according to claim 1 for transfection of cells or tissues with nucleic acid and/or a part thereof and/or nucleic acid derivative in vivo, excluding the transfection of human embryos for industrial or commercial purposes and excluding the modification of a human germ line.
18 . A method of administering a medicament comprising the compound of general formula (I) according to claim 1 for silencing or activating chromosomal gene(s), silencing or activating immunogenes, inhibiting or activating signaling pathways, editing genome or transcriptome, or enabling the expression of the protein(s) encoded by a nucleic acid or for a prophylactic vaccine or for cosmetic preparations in delivering an active ingredient to a site of action.
19 . A method of administering a medicament comprising the compound of general formula (I) according to claim 1 for gene therapy.
20 . The compound of general formula (I), according to claim 1 wherein all R 1 in the compound are different.
21 . The compound of general formula (I), according to claim 1 wherein the compound of general formula (I) is selected from the group consisting of: